Marketing Research and Consulting for the Pharma and Biotech Industries
Perspectives
Marketing Research: Converting Change into Opportunity
What happens to marketing research when marketing budgets are decreased? Marketing research needs to find new ways to do more with less, to change…..you’ve heard it all before... ...
August 22nd, 2011 Read MoreIt’s Not What the Data Says, but What I Can Do With the Data
This was a direct and recent quote from the CEO of a biotech client. Senior executives are not focused on methodology but on whether a study yields actionable findings they can use to make decisions. Yet, attending a couple ...
January 18th, 2011 Read MoreOnly those who risk going too far, find out how far they can go. T. S. Eliot
Most pharma companies have developed research templates to determine what research to conduct prior to the launch of a product, to evaluate its progress over time, or for conducting life cycle research. While every company thinks their templates are unique, ...
August 16th, 2010 Read MoreThe Yin of Marketing Research
Most people think of marketing research as being about information, data, numbers, etc. I don’t. Marketing research is about understanding of customers and converting understanding into a story, images, charts that management will remember, re-use and re-purpose. As marketing research ...
June 25th, 2010 Read MoreThe Next Five Years Will Redefine Pharma and Pharma MR
The world of pharma is undergoing dramatic change and those that adapt to these changes the most quickly will thrive and those who don’t will likely not survive. The same is true for Pharma MR. How can we expect Pharma ...
May 16th, 2010 Read MoreChange Isn’t Just Smart, It’s a Mandate
The pharmaceutical and biotech industries continue to undergo dramatic change. What worked in the past may no longer work in the future. For those in marketing research, this change presents a rare opportunity. We have the potential to break away ...
March 28th, 2010 Read MoreMarketing Research: Confidence vs. Conviction
The difference between a crisis and an opportunity is often how quickly you learn about it and take the appropriate action: progress over perfect. Getting imperfect information assembled and disseminated quickly is often far more valuable than conveying more perfect ...
July 29th, 2009 Read MoreKim Slocum Quoted in “Obamaceuticals”, PharmaVOICE
Click Here to view this article. (PDF Format) ...
July 2nd, 2009 Read MoreThere are no do-overs
There are no do-overs when presenting to senior management. From thirty years’ worth of experience presenting information to the senior executives in pharma and biotech, here’s what they want: Synthesis, not analysis Clarity of thinking Concise presentations Actionable conclusions ...
May 11th, 2009 Read MoreHealth Care – Rational or Rationed
That was the title of a talk delivered back in 1996 by Dr. George Poste. At that time, George had recently retired from his position as head of Research for SmithKline Beecham (pre-Glaxo). I found the talk fascinating because it ...
April 28th, 2009 Read MoreOffice: 215.863.8160 | Fax: 215.830.5051 | Email: info@healogix.com